Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D

Exelixis Inc. (NASDAQ:EXEL) is one of the best growth stocks to buy for the next 2 years. On August 29, Exelixis Inc. announced the appointment of Dana T. Aftab, Ph.D., as its new Executive Vice President, Research & Development. In this role, he will oversee all aspects of the company’s drug discovery, translational research, product development, and medical affairs.

Dr. Aftab has been with Exelixis for more than 25 years, having joined the company in 1998. Most recently, he served as Executive Vice President, Discovery & Translational Research & Chief Scientific Officer since December 2022. He has been a key figure in the discovery and development of the company’s flagship medicine, CABOMETYX (cabozantinib), which is a leading tyrosine kinase inhibitor in the US for treating advanced renal cell carcinoma and advanced neuroendocrine tumors.

This appointment follows the departure of Amy Peterson, M.D., who had served as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer since August 2023.

Exelixis Inc. (NASDAQ:EXEL) is an oncology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers in the US.

While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.